Treatment with Platelet-Rich Plasma: an Evidence Based Case Report of Leprosy Ulcers
DOI:
https://doi.org/10.36408/mhjcm.v13i2.1493Keywords:
platelet rich plasma (PRP), leprosy ulcer, TGF-β1, PDGF, collagen densityAbstract
Introduction: Leprosy foot ulcers occur in patients with leprosy-related neurological disorders and are classified as grade 2 disabilities. These chronic, non-healing ulcers represent a significant clinical challenge. Platelet rich plasma (PRP) application has emerged as a breakthrough treatment.
Case report: Two females (aged 48 and 58) with multibacillary leprosy presented with chronic midfoot ulcers persisting for 16 and 24 weeks. At baseline, ulcer areas were measured and biopsies were performed to assess TGF-β1, PDGF, and collagen density. Follow-up measurements for biomarkers occurred on day 13, and ulcer area was reassessed on day 41.
Discussion: Both patients received standard therapy plus PRP, resulting in reduced ulcer area, increased TGF-β1, and higher collagen density. PDGF levels increased in one patient but decreased in the other. PRP promotes epithelial and endothelial cell proliferation during neovascularization and stimulates extracellular matrix synthesis. Furthermore, it modulates the inflammatory response, facilitating tissue regeneration by balancing the immune system.
Conclusion: Combining standard therapy with PRP shows strong potential for healing chronic leprosy ulcers. Results demonstrated reduced ulcer area, increased TGF-β1, and improved collagen density, though PDGF levels remained inconsistent
Downloads
References
1. Riyaz N, Sehgal VN. Leprosy: Trophic Skin Ulcers. Skinmed. 2017;15(1):45–51.
2. Sehgal VN, Prasad PVS, Kaviarasan PK, Rajan D. Trophic Skin Ulceration in Leprosy: Evaluation of The Efficacy of Topical Phenytoin Sodium Zinc Oxide Paste. Int J Dermatol. 2014;53(7):873–8.
3. Leon KE, Jacob JT, Franco-paredes C, Kozarsky PE, Wu HM, Fairley JK. Delayed Diagnosis , Leprosy Reactions , and Nerve Injury Among Individuals With Hansen ’ s Disease Seen at a United States Clinic. 2014;1–4.
4. Seid E. Prevalence , patterns and determinants of peripheral neuropathy among leprosy patients in Northeast Ethiopia : A retrospective study. 2025;1–16. Available from: https://doi.org/10.1371/journal.pntd.0012944
5. Wallace HA, Zito PM. Wound Healing Phases [Internet]. StatPearls. 2019 [cited 2021 May 7]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29262065
6. Wong RSY, Tan T, Pang ASR, Srinivasan DK. The Role of Cytokines in Wound Healing: from Mechanistic insights to Therapeutic Applications. Explor Immunol. 2025;5(Figure 1):1–22.
7. Andersen JG. Plantar ulcers in leprosy. Lepr Rev. 1961;32(1):15–21.
8. KEMENKES RI. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kusta. 2020.
9. Muslimin, Rachmawati B, Kabulrachman. Management of Leprosy Ulcers : A Review Article. 2026;98:51–66.
10. Anandan V, Jameela WA, Saraswathy P, Sarankumar S. Platelet Rich Plasma: Efficacy in Treating Trophic Ulcers in Leprosy. J Clin Diagnostic Res. 2016;10(10):WC06–9.
11. Sari DK, Listiawan MY, Indramaya DM. Efek Pemberian Topikal Gel Plasma Kaya Trombosit ( PKT ) pada Proses Penyembuhan Ulkus Plantar Kronis Pasien Kusta ( The Effects of Platelet Rich Plasma Topical Gel on Chronic Plantar Ulcer Healing in Leprosy Patient ). Berk Ilmu Kesehat Kulit dan Kelamin. 2016;8(3):1–7.
12. Saha S, Patra AC, Gowda SP, Mondal N, Rahaman S, Ahmed SKS, et al. Effectiveness and Safety of Autologous Platelet-Rich Plasma Therapy with Total Contact Casting Versus Total Contact Casting Alone in Treatment of Trophic Ulcer in Leprosy: An Observer-Blind, Randomized Controlled Trial. Indian J Dermatol Venereol Leprol. 2020;86(3):262–71.
13. Sakaria AD, Alva B V. Platelet Rich Plasma : a Novel Therapy in Chronic Wounds. 2023;10(8):1295–8.
14. Conde-Montero E, de la Cueva Dobao P, Martínez González JM. Platelet-Rich Plasma for the Treatment of Chronic Wounds: Evidence to Date. Chronic Wound Care Manag Res. 2017;Volume 4:107–20.
15. Napit IB, Shrestha D, Neupane K, Adhikari A, Dhital R, Koirala R, et al. Autologous blood products : Leucocyte PRF ) and and Platelets Rich Fibrin ( L- Platelets Rich Plasma ( PRP ) gel to promote cutaneous ulcer healing – a systematic review. 2023;1–10.
16. Mukherjee A, Das S, Roy S, Patra AC, Ghosh A, Amrita, et al. Effectiveness and safety of topical autologous platelet-rich fibrin membrane with total contact cast versus perilesional injectable autologous platelet-rich plasma therapy with total contact cast in trophic ulcer due to leprosy : A randomised controlled t. 2025;91(2):163–71.
17. Rather S, Kour S, Aslam A. Autologous Subcutaneous Platelet-Rich Plasma in the Management of Non-Healing Trophic Ulcer in Leprosy. Indian J Lepr. 2023;95:221–4.
18. Vendhan S, Neema S, Vasudevan B, Krishnan L, Gera V. Platelet-rich fibrin therapy in the management of nonhealing trophic ulcers due to underlying leprous neuropathy. 2024;17(3):262–5.
19. Napit IB, Shrestha D, Bishop J et al. An Individual Randomised Efficacy Trial of Autologous Blood Products, Leukocyte and Platelet-Rich Fibrin (L-PRF), to Promote Ulcer Healing in Leprosy in Nepal: the TABLE Trial Protocol. Trials. 2021;22(1):1–13.
20. Suryawati N, Praharsini IGAA, Juliyanti J. Management Non-healing Trophic Ulcer in a Leprosy Patient with Combination of Injection and Topical Platelet Rich Plasma. J Ski Stem Cell. 2020;6(3):e101432.
21. World Health Organization. Global Leprosy (Hansen disease) Update, 2023: Elimination of Leprosy Disease is Possible – Time to Act! Wkly Epidemiol Rec Relev épidémiologique Hebd. 2024;99(37):501-21p.
22. Reinar LM, Forsetlund L, Lehman LF, Brurberg KG. Interventions for Ulceration and Other Skin Changes Caused by Nerve Damage in Leprosy. Cochrane Database Syst Rev. 2019;2019(7):CD012235.
23. Patel H, Pundkar A, Shrivastava S, Chandanwale R, Jaiswal AM. A Comprehensive Review on Platelet-Rich Plasma Activation: A Key Player in Accelerating Skin Wound Healing. Cureus. 2023;15(11):e48943.
24. Suthar M, Gupta S, Bukhari S, Ponemone V. Treatment of Chronic Non-Healing Ulcers Using Autologous PlateletRrich Plasma: A Case Series. J Biomed Sci. 2017;24(1):1–10.
25. Yilmaz S, Aksoy E, Doganci S, Yalcinkaya A, Diken AI, Cagli K. Autologous Platelet-Rich Plasma in Treatment of Chronic Venous Leg Ulcers: A Prospective Case Series. Vascular. 2015;23(6):580–5.
26. Kontopodis N, Tavlas E, Papadopoulos G, Pantidis D, Kafetzakis A, Chalkiadakis G, et al. Effectiveness of Platelet-Rich Plasma to Enhance Healing of Diabetic Foot Ulcers in Patients with Concomitant Peripheral Arterial Disease and Critical Limb Ischemia. Int J Low Extrem Wounds. 2016;15(1):45–51.
27. Mohammadi MH, Molavi B, Mohammadi S, Nikbakht M, Mohammadi AM, Mostafaei S, et al. Evaluation of Wound Healing in Diabetic Foot Ulcer Using Platelet-Rich Plasma Gel: A Single-Arm Clinical Trial. Transfus Apher Sci. 2017;56(2):160–4.
28. Ahmed M, Reffat SA, Hassan A, Eskander F. Platelet-Rich Plasma for the Treatment of Clean Diabetic Foot Ulcers. Ann Vasc Surg. 2017;38:206–11.
29. Tsachiridi M, Galyfos G, Andreou A, Sianou A, Sigala F, Zografos G, et al. Autologous Platelet-Rich Plasma for Nonhealing Ulcers: A Comparative Study. Vasc Spec Int. 2019;35(1):22–7.
30. Zhang W, Guo Y, Kuss M, Shi W, Aldrich AL, Untrauer J, et al. Platelet Rich Plasma for the Treatment of Tissue Infection: Preparation and clinical evaluation. Tissue Eng - Part B Rev. 2019;25(3):225–36.
31. Reksodiputro MH, Harahap AR, Setiawan L, Yosia M. A Modified Preparation Method of Ideal Platelet-Rich Fibrin Matrix From Whole Blood. Front Med. 2021;8(August):1–9.
32. Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C, et al. TGF-β Signaling in Health, Disease, and Therapeutics. Signal Transduct Target Ther [Internet]. 2024;9(1). Available from: http://dx.doi.org/10.1038/s41392-024-01764-w
33. Alfarizi R, Yuniati R, Mundhofir FEP, Wijayahadi N, Nindita Y. Correlation between TGF-β Levels and Degree of Wound Healing in Leprosy Ulcer Patients: An Observational Study at dr. Rehatta Regional Hospital Jepara. J Kedokt Diponegoro (Diponegoro Med Journal). 2024;13(3):158–61.
34. Zhang J, Guan M, Xie C, Luo X, Zhang Q, Xue Y. Increased Growth Factors Play a Role in Wound Healing Promoted by Noninvasive Oxygen-Ozone Therapy in Diabetic Patients with Foot Ulcers. Oxid Med Cell Longev. 2014;2014:273475.
35. Wang J, You J, Gong D, Xu Y, Yang B, Jiang C. PDGF-BB Induces Conversion, Proliferation, Migration, and Collagen Synthesis of Oral Mucosal Fibroblasts through PDGFR-β/PI3K/AKT Signaling Pathway. Cancer Biomarkers. 2021;30(4):407–15.
36. Bartold M, Ivanovski S. Biological Processes and Factors involved in Soft and Hard Tissue Healing. Vol. 97, Periodontology 2000. 2025. p. 16–42.
37. Ren X, Zhao M, Lash B, Martino MM, Julier Z. Growth Factor Engineering Strategies for Regenerative Medicine Applications. Front Bioeng Biotechnol. 2020;7(January):1–9.
38. Nagaraju U, Sundar P, Agarwal P, Raju B, Kumar M. Autologous Platelet-Rich Fibrin Matrix in Non-Healing Trophic Ulcers in Patients with Hansen’s Disease. J Cutan Aesthet Surg. 2017;10(1):3–7.
39. Yümün G, Kahraman C, Kahraman N, Yalçinkaya U, Akçilar A, Akgül E, et al. Effects of Hyperbaric Oxygen Therapy Combined with Platelet-Rich Plasma on Diabetic Wounds: An Experimental Rat Model. Arch Med Sci. 2016;12(6):1370–6.
40. Duran A, Yaşar Ş, Aytekin S, Güneş P, Adaleti R, Duran A. Clinical and Histopathological Evaluation of the Effects of Platelet Rich Plasma, Platelet Poor Plasma and Topical Serum Physiologic Treatment on Wound Healing Caused by Radiofrequency Electrosurgery in Rats. Turkderm Turkish Arch Dermatology Venereol. 2018;52(2):44–50.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Muslimin Muslimin, Rachmawati Banundari, Kabulrachman Kabulrachman (Author)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
